Working… Menu

DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (DERIVe)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03688178
Recruitment Status : Suspended (Pending new testing requirements from the FDA)
First Posted : September 28, 2018
Last Update Posted : August 26, 2019
Celldex Therapeutics
Information provided by (Responsible Party):
Gary Archer Ph.D., Duke University

No Study Results Posted on for this Study
Recruitment Status : Suspended
Estimated Primary Completion Date : March 1, 2025
Estimated Study Completion Date : March 1, 2025